Groundbreaking Stem Cell Clinical Trial for Retinal Disease Treats Its First Patient
Using a stem cell-derived therapeutic developed over more than a decade in Dr. David Gamm’s lab at UW–Madison, BlueRock Therapeutics has treated the first patient in a new Phase 1/2a clinical trial aimed at a group of inherited retinal disorders (including RP and cone-rod dystrophy). The initiative is the result of a strategic research alliance formed in …